Astellas Pharma Inc. (ALPMY)
USD 9.3
(0.98%)
USD 9.3
(0.98%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 194.81 Billion JPY | -21.09% |
| 2023 | 246.87 Billion JPY | 30.52% |
| 2022 | 241.51 Billion JPY | -7.37% |
| 2021 | 220.31 Billion JPY | -6.44% |
| 2020 | 314.75 Billion JPY | 0.64% |
| 2019 | 313.72 Billion JPY | 2.23% |
| 2018 | 284.75 Billion JPY | -1.21% |
| 2017 | 347.53 Billion JPY | 0.13% |
| 2016 | 332.58 Billion JPY | 16.22% |
| 2015 | 258.23 Billion JPY | 18.17% |
| 2014 | 187.93 Billion JPY | 16.85% |
| 2013 | 180.09 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 86.36 Billion JPY | -93.79% |
| 2024 Q1 | 87.44 Billion JPY | 419.53% |
| 2024 FY | - JPY | -14.13% |
| 2024 Q2 | 75.4 Billion JPY | -36.05% |
| 2024 Q3 | 86.69 Billion JPY | 44.15% |
| 2023 FY | - JPY | 30.52% |
| 2023 Q4 | 76.35 Billion JPY | -31.61% |
| 2023 Q3 | 111.65 Billion JPY | 0.12% |
| 2023 Q2 | 111.51 Billion JPY | 21.68% |
| 2023 Q1 | 91.64 Billion JPY | 94.09% |
| 2022 Q4 | 47.21 Billion JPY | -47.78% |
| 2022 FY | - JPY | -7.37% |
| 2022 Q3 | 90.41 Billion JPY | 11.09% |
| 2022 Q2 | 81.39 Billion JPY | 0.9% |
| 2022 Q1 | 80.67 Billion JPY | 23.26% |
| 2021 Q4 | 65.44 Billion JPY | -27.88% |
| 2021 Q2 | 44.24 Billion JPY | -43.88% |
| 2021 Q1 | 78.84 Billion JPY | 72.34% |
| 2021 FY | - JPY | -6.44% |
| 2021 Q3 | 90.74 Billion JPY | 105.1% |
| 2020 Q3 | 93.38 Billion JPY | -6.54% |
| 2020 Q1 | 94.82 Billion JPY | 8.19% |
| 2020 FY | - JPY | 0.64% |
| 2020 Q2 | 99.92 Billion JPY | 5.37% |
| 2020 Q4 | 45.74 Billion JPY | -51.01% |
| 2019 Q4 | 87.64 Billion JPY | -11.42% |
| 2019 Q2 | 79.4 Billion JPY | -0.59% |
| 2019 FY | - JPY | 2.23% |
| 2019 Q1 | 79.88 Billion JPY | -25.45% |
| 2019 Q3 | 98.94 Billion JPY | 24.6% |
| 2018 Q4 | 107.14 Billion JPY | 6.74% |
| 2018 Q3 | 100.38 Billion JPY | 45.01% |
| 2018 Q2 | 69.22 Billion JPY | 15.54% |
| 2018 Q1 | 59.91 Billion JPY | 4.13% |
| 2018 FY | - JPY | -1.21% |
| 2017 Q3 | 90.72 Billion JPY | 13.32% |
| 2017 Q4 | 57.54 Billion JPY | -36.57% |
| 2017 FY | - JPY | 0.13% |
| 2017 Q1 | 109.28 Billion JPY | 57.03% |
| 2017 Q2 | 80.05 Billion JPY | -26.74% |
| 2016 Q1 | 79.52 Billion JPY | -3.89% |
| 2016 FY | - JPY | 16.22% |
| 2016 Q4 | 69.59 Billion JPY | -31.18% |
| 2016 Q3 | 101.12 Billion JPY | 14.33% |
| 2016 Q2 | 88.44 Billion JPY | 11.23% |
| 2015 FY | - JPY | 18.17% |
| 2015 Q2 | 68.27 Billion JPY | 3.75% |
| 2015 Q4 | 82.73 Billion JPY | 9.53% |
| 2015 Q3 | 75.53 Billion JPY | 10.64% |
| 2015 Q1 | 65.8 Billion JPY | 39.64% |
| 2014 Q2 | 62.44 Billion JPY | 17.8% |
| 2014 Q3 | 81.96 Billion JPY | 31.27% |
| 2014 FY | - JPY | 16.85% |
| 2014 Q4 | 47.12 Billion JPY | -42.51% |
| 2014 Q1 | 53 Billion JPY | 59.25% |
| 2013 Q4 | 33.28 Billion JPY | -47.19% |
| 2013 Q3 | 63.03 Billion JPY | 27.09% |
| 2013 FY | - JPY | 0.0% |
| 2013 Q2 | 49.59 Billion JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | -1365.908% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | -903.317% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -16868.898% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 490753.57% |
| Novartis AG | 19.51 Billion USD | -898.134% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -67512.366% |